Innovation
Innovation drives disease prevention
We are at the forefront of health-related advances in science and technology, working to create innovative solutions to a range of healthcare challenges.
Investors
We announced our quarter 1 2024 results on Wednesday, May 1st.
Press releases
- GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA
- GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
- Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features